FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322775265> ?p ?o ?g. }

• W4322775265 endingPage "09" @default.
• W4322775265 startingPage "P4" @default.
• W4322775265 abstract "Abstract Background: The pathologic complete response (pCR) rate in inflammatory breast cancer (IBC) patients is worse than in non-IBC patients; new drug combinations are warranted to improve pCR rates across all IBC molecular subtypes. Based on our preclinical data, we added neratinib to standard neoadjuvant chemotherapy in both HER2+ (synergy) and HER2-/hormone receptor (HR)+ (high frequency of ERBB2 mut) untreated IBC, as a single-center, non-randomized phase I/II trial. Patients and Method: This study enrolled three cohorts: Cohort I phase Ib (C1P1B), Cohort I Phase II (C1P2) and Cohort II (C2). In C1P1B to determine the recommended phase 2 dose (RP2D), we enrolled patients with HER2+ metastatic or locally advanced breast cancer. Patients received paclitaxel/trastuzumab/pertuzumab (THP) + neratinib x 4 cycles (up to 8 cycles per physician’s discretion). For C1P2 and C2, we enrolled Stage III – IV primary IBC patients. In C1P2, patients with HER2+ IBC received neratinib (RP2D) combined with THP x 4 cycles followed by doxorubicin/cyclophosphamide (AC) x 4 cycles. Per stage I design, 11 patients were enrolled with plan to enroll 20 more patients in Stage II if at least 6 had a pCR. In C2, patients with HER2-/HR+ IBC received neratinib 200 mg/day combined with paclitaxel x 4 cycles followed by AC x 4 cycles. Stage I design planned for enrollment of 16 patients with enrollment of 15 more patients on stage II, if at least 2 Stage I patients had pCR. In all three cohorts, patients initiated prophylactic anti-diarrheal medication (loperamide & budesonide) with the first dose of neratinib. Results: From 2018 to 2022, thirty-four patients were enrolled and treated (n=4 C1P1B, n=14 C1P2, n=16 C2). In C1P1B, observed DLTs (dose limiting toxicities) were Grade (Gr) 2 Diarrhea, n=2 (50%); Gr3 diarrhea, n=2 (50%); 2 patients had a serious adverse event (SAE); 3 patients (55%) had Gr2 nausea. The RP2D was established at 80 mg/day (dose level 0). For patients in C1P2, the most frequently occurring adverse events (AEs) included Gr2 Alopecia, n=14 (100%); Gr2&3 Diarrhea, n=14 (100%); Gr2/3 Nausea, n=12 (86%); Gr2/3 Anemia, n=7 (50%); Gr2/3 Fatigue, n=8 (57%); Gr2/3 Hypokalemia, n=6 (57%); and Gr2/3 Neutrophil count decreased, n= 7 (50%). 6 patients had an SAE. Of the first 11 patients, 5 (46%) had pCR, 1 (9%) RCB-1, 1 (9%) RCB-II and 1 (9%) RCB-III. Three patients stopped study treatment for toxicity (27%), were non-evaluable and replaced. Of these, one had RCB-III (33.3%), one progression of disease (PD) (33.3%), and one came off study for toxicity (33.3%). Rather than replacing additional non-evaluable patients, the study was closed to new patient accrual. In C2, the most frequently occurring AEs were Gr2 diarrhea, n=7(44%); Gr3 diarrhea, n=8 (50%); Gr2 alopecia, n=14 (88%); Gr2/3 Anemia, n=10 (63%); Gr2/3 Nausea, n=7 (44%); Gr2/3 Neutropenia, n= 7 (44%). 3 patients had an SAE. Of 16 patients in this cohort, 1 had pCR (6%), 5 RCB-II (31%), 4 RCB-III (25%), 3 came off study for toxicity (19%) and 3 had PD (19%). C2 also closed to new patient accrual given the high toxicity profile. Conclusion: The addition of neratinib did not improve the pCR rate in HER2+ or HER2-/HR+ subtypes of IBC, and increased toxicities were observed. The trial closed to new patient entry March 2022. However, some patients achieved significant response. Biomarker analysis is ongoing. Evaluable participants will continue long-term follow-up per protocol. Acknowledgments: This study is supported by PUMA Biotechnology. Citation Format: Angela N. Marx, Megumi Kai, Min Fu, Hope E. Murphy, Jie S. Willey, Huiming Sun, Angela Alexander, Roland L. Bassett, Gary J. Whitman, H. T. Carisa Le-Petross, Miral Patel, Banu K. Arun, Sausan Abouharb, Parijatham S. Thomas, Carlos H. Barcenas, Nuhad K. Ibrahim, Vicente Valero, Naoto T. Ueno, Rachel M. Layman, Bora Lim, Wendy Woodward, Anthony Lucci. A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+/HER2- IBC [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-06-09." @default.
• W4322775265 created "2023-03-03" @default.
• W4322775265 creator A5006696681 @default.
• W4322775265 creator A5016731809 @default.
• W4322775265 creator A5019135959 @default.
• W4322775265 creator A5027845051 @default.
• W4322775265 creator A5030150444 @default.
• W4322775265 creator A5031867067 @default.
• W4322775265 creator A5033932889 @default.
• W4322775265 creator A5034373609 @default.
• W4322775265 creator A5042475462 @default.
• W4322775265 creator A5053893309 @default.
• W4322775265 creator A5055141762 @default.
• W4322775265 creator A5056364585 @default.
• W4322775265 creator A5063132073 @default.
• W4322775265 creator A5064168158 @default.
• W4322775265 creator A5065665159 @default.
• W4322775265 creator A5070262949 @default.
• W4322775265 creator A5070852357 @default.
• W4322775265 creator A5077026571 @default.
• W4322775265 creator A5080832682 @default.
• W4322775265 creator A5086574351 @default.
• W4322775265 creator A5088814426 @default.
• W4322775265 creator A5091770828 @default.
• W4322775265 date "2023-03-01" @default.
• W4322775265 modified "2023-09-26" @default.
• W4322775265 title "Abstract P4-06-09: A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+/HER2- IBC" @default.
• W4322775265 doi "https://doi.org/10.1158/1538-7445.sabcs22-p4-06-09" @default.
• W4322775265 hasPublicationYear "2023" @default.
• W4322775265 type Work @default.
• W4322775265 citedByCount "0" @default.
• W4322775265 crossrefType "journal-article" @default.
• W4322775265 hasAuthorship W4322775265A5006696681 @default.
• W4322775265 hasAuthorship W4322775265A5016731809 @default.
• W4322775265 hasAuthorship W4322775265A5019135959 @default.
• W4322775265 hasAuthorship W4322775265A5027845051 @default.
• W4322775265 hasAuthorship W4322775265A5030150444 @default.
• W4322775265 hasAuthorship W4322775265A5031867067 @default.
• W4322775265 hasAuthorship W4322775265A5033932889 @default.
• W4322775265 hasAuthorship W4322775265A5034373609 @default.
• W4322775265 hasAuthorship W4322775265A5042475462 @default.
• W4322775265 hasAuthorship W4322775265A5053893309 @default.
• W4322775265 hasAuthorship W4322775265A5055141762 @default.
• W4322775265 hasAuthorship W4322775265A5056364585 @default.
• W4322775265 hasAuthorship W4322775265A5063132073 @default.
• W4322775265 hasAuthorship W4322775265A5064168158 @default.
• W4322775265 hasAuthorship W4322775265A5065665159 @default.
• W4322775265 hasAuthorship W4322775265A5070262949 @default.
• W4322775265 hasAuthorship W4322775265A5070852357 @default.
• W4322775265 hasAuthorship W4322775265A5077026571 @default.
• W4322775265 hasAuthorship W4322775265A5080832682 @default.
• W4322775265 hasAuthorship W4322775265A5086574351 @default.
• W4322775265 hasAuthorship W4322775265A5088814426 @default.
• W4322775265 hasAuthorship W4322775265A5091770828 @default.
• W4322775265 hasConcept C121608353 @default.
• W4322775265 hasConcept C126322002 @default.
• W4322775265 hasConcept C143998085 @default.
• W4322775265 hasConcept C2775930923 @default.
• W4322775265 hasConcept C2776694085 @default.
• W4322775265 hasConcept C2776755627 @default.
• W4322775265 hasConcept C2777757722 @default.
• W4322775265 hasConcept C2779413316 @default.
• W4322775265 hasConcept C2779572924 @default.
• W4322775265 hasConcept C2779786085 @default.
• W4322775265 hasConcept C2780839634 @default.
• W4322775265 hasConcept C530470458 @default.
• W4322775265 hasConcept C71924100 @default.
• W4322775265 hasConcept C72563966 @default.
• W4322775265 hasConcept C90924648 @default.
• W4322775265 hasConceptScore W4322775265C121608353 @default.
• W4322775265 hasConceptScore W4322775265C126322002 @default.
• W4322775265 hasConceptScore W4322775265C143998085 @default.
• W4322775265 hasConceptScore W4322775265C2775930923 @default.
• W4322775265 hasConceptScore W4322775265C2776694085 @default.
• W4322775265 hasConceptScore W4322775265C2776755627 @default.
• W4322775265 hasConceptScore W4322775265C2777757722 @default.
• W4322775265 hasConceptScore W4322775265C2779413316 @default.
• W4322775265 hasConceptScore W4322775265C2779572924 @default.
• W4322775265 hasConceptScore W4322775265C2779786085 @default.
• W4322775265 hasConceptScore W4322775265C2780839634 @default.
• W4322775265 hasConceptScore W4322775265C530470458 @default.
• W4322775265 hasConceptScore W4322775265C71924100 @default.
• W4322775265 hasConceptScore W4322775265C72563966 @default.
• W4322775265 hasConceptScore W4322775265C90924648 @default.
• W4322775265 hasIssue "5_Supplement" @default.
• W4322775265 hasLocation W43227752651 @default.
• W4322775265 hasOpenAccess W4322775265 @default.
• W4322775265 hasPrimaryLocation W43227752651 @default.
• W4322775265 hasRelatedWork W2030434439 @default.
• W4322775265 hasRelatedWork W2050439103 @default.
• W4322775265 hasRelatedWork W2092771806 @default.
• W4322775265 hasRelatedWork W2218005127 @default.
• W4322775265 hasRelatedWork W2331572872 @default.
• W4322775265 hasRelatedWork W2401868633 @default.
• W4322775265 hasRelatedWork W2598405586 @default.
• W4322775265 hasRelatedWork W2733880205 @default.
• W4322775265 hasRelatedWork W2969515167 @default.
• W4322775265 hasRelatedWork W4322775265 @default.

• next